Lysosomes News and Research

RSS

D614G mutation promotes lysosomal trafficking of SARS-CoV-2 spike protein

In the current COVID-19 pandemic, SARS-CoV-2 has led to millions of infections worldwide, with over 1.5 million deaths.

14 Dec 2020

New insight into role of autophagy in controlling SARS-CoV-2 infection

A team of researchers at the University of Manitoba in Canada said that nanoparticle targeting of autophagy at the sites could be a potent tool to effectively overcome COVID-19 while preventing the common adverse effects of the drug.

2 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Researchers identify CLCN6 as disease gene for severe lysosomal neurodegenerative disorder

A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder. Scientists from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and the Max Delbrück Center für Molekulare Medizin, together with an international team of researchers, have now analyzed the effect of a point mutation that was found in three unrelated affected children.

19 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Raman microscopy-based approach uses gold nanoparticles for visualizing small-molecule drugs

Successful drug development has a significant impact on people's quality of life worldwide. Being able to track how molecules get into target cells, and observing what they do when they are inside, is key to identifying the best candidates.

18 Nov 2020

Discovery of 'Achilles heel' in protein crucial to HIV virulence could lead to new class of drugs

The discovery of a potential "Achilles heel" in Nef, the protein that is crucial to HIV virulence and its capacity to trigger AIDS, paves the way for the development of a new class of drugs against the virus.

17 Nov 2020

Novel molecules show potential for future cancer therapies

Cancers sometimes escape our immune defenses because of the over-activity of molecular signaling systems, called checkpoint processes. Now we may be able to fight back using a new range of molecules, researchers in China report in the European Journal of Medicinal Chemistry.

3 Nov 2020

Study reveals molecular mechanism that increases the invasiveness of radioresistant cancer cells

Scientists have revealed the molecular mechanism regulating the trafficking of lysosomes that increases the invasiveness of radioresistant cancer cells following radiotherapy.

30 Oct 2020

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Enzyme SSH1 impairs the disposal of damaged tau and neurotoxic mitochondria

In a healthy brain, the multistep waste clearance process known as autophagy routinely removes and degrades damaged cell components - including malformed proteins like tau and toxic mitochondria.

12 Oct 2020

Blocking the self-destruction process of enzymes can mitigate age-related diseases

Stopping the cannibalistic behavior of a well-studied enzyme could be the key to new drugs to fight age-related diseases, according to a new study published online in Nature Cell Biology.

30 Sep 2020

Study unravels how lysosomal damage response pathways prevent kidney injury

Human cells need to work like well-oiled machines to keep our bodies running as they should. Waste products such as misfolded proteins, damaged cellular components, and carbohydrates get in the way and must be quickly disposed of.

28 Sep 2020

Chaperone-mediated autophagy could be a new therapeutic target for spinocerebellar ataxia

A research team from Kumamoto University, Japan has developed an animal model that reproduces motor dysfunction and cerebellar neurodegeneration similar to that in spinocerebellar ataxia (SCA) by inhibiting chaperone-mediated autophagy (CMA) in cerebellar neurons.

23 Sep 2020

Study offers hope for treatment of Krabbe disease

In one out of 100,000 infants, a mutation in the GALC gene causes an incurable, always fatal disorder known as infantile Krabbe disease, or globoid cell leukodystrophy. Most children with the condition die before they turn 2.

26 Aug 2020

Exosomes: The cancer cell communication mechanism

Professor Deborah Goberdhan speaks to News-Medical about her team's latest research into cancer cells, and the mechanisms they use to communicate.

26 Aug 2020

Antimalarial drug shows in vitro activity against SARS-CoV-2 and flu viruses

Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.

30 Jul 2020

High ACE2 Expression on pancreatic islet cells during inflammation could explain new-onset diabetes in COVID-19

A new study suggests that the SARS-CoV-2 infection may be linked to the onset of diabetes, via the infection of pancreatic islet beta cells, which produce insulin.

27 Jul 2020

Study shows how mast cells regulate calcium levels to control the immune response

Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies. An Ludwig-Maximilian-Universitaet (LMU) in Munich team has dissected how mast cells regulate their calcium levels to keep the immune response under control.

23 Jul 2020

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Harvard University's Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.